Recommendations for Implementing Hepatitis C Virus Care in Homeless Shelters: The Stakeholder Perspective.
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
03
10
2019
accepted:
07
02
2020
entrez:
5
5
2020
pubmed:
5
5
2020
medline:
5
5
2020
Statut:
epublish
Résumé
Compared with the general population, homeless individuals are at higher risk of hepatitis C infection (HCV) and may face unique barriers in receipt of HCV care. This study sought the perspectives of key stakeholders toward establishing a universal HCV screening, testing, and treatment protocol for individuals accessing homeless shelters. Four focus groups were conducted with homeless shelter staff, practice providers, and social service outreach workers (n = 27) in San Francisco, California, and Minneapolis, Minnesota. Focus groups evaluated key societal, system, and individual-level facilitators and barriers to HCV testing and management. Interviews were transcribed and analyzed thematically. The societal-level barriers identified were lack of insurance, high-out-of-pocket expenses, restriction of access to HCV treatment due to active drug and/or alcohol use, and excessive paperwork required for HCV treatment authorization from payers. System-level barriers included workforce constraints and limited health care infrastructure, HCV stigma, low knowledge of HCV treatment, and existing shelter policies. At the individual level, client barriers included competing priorities, behavioral health concerns, and health attitudes. Facilitators at the system level for HCV care service integration in the shelter setting included high acceptability and buy in, and linkage with social service providers.
Identifiants
pubmed: 32363316
doi: 10.1002/hep4.1492
pii: HEP41492
pmc: PMC7193125
doi:
Types de publication
Journal Article
Langues
eng
Pagination
646-656Subventions
Organisme : NIAAA NIH HHS
ID : K24 AA022523
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA007250
Pays : United States
Organisme : NIDA NIH HHS
ID : UG1 DA015815
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.
Références
Drug Alcohol Depend. 2004 Jul 15;75(1):89-95
pubmed: 15225892
J Forensic Nurs. 2013 Jul-Sep;9(3):161-70
pubmed: 24158154
Int J Drug Policy. 2019 Oct;72:129-137
pubmed: 30962036
Liver Int. 2013 Aug;33(7):999-1007
pubmed: 23509897
J Community Health. 2019 Dec;44(6):1044-1054
pubmed: 31127412
Harm Reduct J. 2018 Aug 15;15(1):42
pubmed: 30111327
Sex Transm Dis. 2018 Jul;45(7):494-504
pubmed: 29465661
Public Health Rep. 2012 Jul-Aug;127(4):407-21
pubmed: 22753984
Harm Reduct J. 2008 Feb 25;5:8
pubmed: 18298862
J Health Psychol. 2017 Sep;22(10):1300-1311
pubmed: 26857543
Int J Drug Policy. 2019 Oct;72:146-159
pubmed: 31147142
Prev Med. 2010 Jan-Feb;50(1-2):63-7
pubmed: 19716379
Dig Dis Sci. 2017 Aug;62(8):1933-1943
pubmed: 28523579
Harm Reduct J. 2017 Sep 29;14(1):67
pubmed: 28962652
J Community Health Nurs. 2014;31(2):103-17
pubmed: 24788048
Prev Chronic Dis. 2014 May 01;11:E72
pubmed: 24784908
Hepatology. 2019 Aug;70(2):476-486
pubmed: 30633811
J Psychiatr Res. 2017 Jan;84:80-89
pubmed: 27701013
J Viral Hepat. 2010 Dec;17(12):839-44
pubmed: 20070504
Hepatology. 2019 Mar;69(3):1020-1031
pubmed: 30398671
BMC Public Health. 2017 Feb 7;17(1):171
pubmed: 28173785
Public Health Rep. 2017 Mar/Apr;132(2):136-139
pubmed: 28135425
PLoS One. 2017 May 19;12(5):e0177341
pubmed: 28542351
Dig Dis Sci. 2011 Jan;56(1):213-9
pubmed: 20972850
AIDS Care. 2004;16 Suppl 1:S43-55
pubmed: 15736821
Drug Alcohol Depend. 2013 Oct 1;132(3):457-65
pubmed: 23578590
Aust Health Rev. 2008 Aug;32(3):570-6
pubmed: 18666886